We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Repurposing Existing Drugs for Coronavirus: Scripps Research COVID-19 Updates

Video   Mar 24, 2020 | Taken from Scripps Research, YouTube


Scripps Research teams are looking for anti-viral drugs that could be given to people already exposed to the novel coronavirus causing the COVID-19 pandemic. One priority is to test already approved drugs, or drugs with significant safety data in humans available, which could be made available to treat coronavirus patients on a much quicker timescale than new therapies.

To do this, Calibr—the drug development division of Scripps Research—is leveraging a unique resource, the ReFRAME drug repurposing collection. With support from the Bill & Melinda Gates Foundation, Calibr compiled ReFRAME, the world’s leading collection of known drugs, comprising over 14,000 compounds that have been approved by the FDA for other diseases or have been extensively tested for human safety.

Visit Technology Networkshubpage to stay updated with all the latest news on the current coronavirus outbreak

More Information

Recommended Videos

Unlocking the Protein Structure of Coronavirus


The novel coronavirus sweeping the globe packs 27 proteins, each adopting a unique, often incredibly complex 3D structure. Each protein is part of the molecular toolkit that the virus uses to infect, replicate, and spread. Understanding the proteins' structures provides a blueprint for drug designs.


Air Pollution Over China Dropped in January, Rebounding in March - Satellite Data


A drop in nitrogen dioxide emissions correlated to the nationwide quarantine in China in January 2020. Two months later the emissions are increasing.


Testimonial: Use of Rotavapors for Drug Discovery and Formulation in Academic Research


Dr. Fabiana Quaglia, Associate Professor of Pharmaceutical Technology at the Faculty of Pharmacy–University of Napoli Federico II, Italy discusses how reliability and smart features of the rotary evaporator, Rotavapor® R-300, let her easily evaporate solvents in particle production for cancer and cystic fibrosis drug development and formulation.



Like what you just watched? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free